AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01336088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX48621
Description: oral administration
Study NCT01336088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT03330496 — intervention group
Intervention type: OTHER
Intervention: Pain Measurement
Description: Measurement of infant responses (behavioral and physiological) during a painful procedure.
Study NCT03013036 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasonography
Study NCT03013036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Study NCT03013036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intravenous midazolam
Study NCT03013036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Study NCT03013036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fentanyl and rocuronium
Study NCT03570515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days, recording their practice on a yoga homework log provided to them.
Study NCT03570515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational film
Description: Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
Study NCT00562198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entacapone and carbidopa
Description: Entacapone 200mg carbidopa 50mg
Study NCT00562198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet 200mg/50mg
Description: Sinemet 200mg/50mg once
Study NCT02241031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPs
Description: MPs are generated from cord blood using a combination of cytokines.
Study NCT02241031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thrombopoietin (TPO) and interleukin-11
Description: Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
Study NCT00151073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT00151073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine
Study NCT00151073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00000437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Tablet and Nicotine Patch
Study NCT00000437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Tablet and Placebo Patch
Study NCT00000437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Tablet and Nicotine Patch
Study NCT00000437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet and Placebo Patch
Study NCT03387462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet
Description: Open label daily emtricitabine/tenofovir disoproxil oral tablet
Study NCT03387462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOT Diary mobile app
Description: DOT Diary mobile application for tracking medication adherence and sexual activities.
Study NCT03062787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)
Description: Intra-articular injection
Study NCT03062787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monovisc® (Sodium hyaluronate)
Description: Intra-articular injection
Study NCT01424020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
Study NCT03694236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated.
Study NCT00629057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-PRO
Description: 1x10e8 TCID50 q 4 wks x 6
Study NCT02040012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZP-531
Study NCT02040012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01744626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292
Description: Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
Study NCT01744626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
Study NCT02471677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elonva
Description: corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
Study NCT02471677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Puregon
Description: follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
Study NCT04238182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wet cupping
Description: This smoker group will receive single wet cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm . Cupping of BL 17 will be done bilaterally.
Study NCT04238182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry cupping
Description: The smoker group will receive single dry cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm. Cupping of BL 17 will be done bilaterally.
Study NCT00458705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT00458705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00458705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study NCT00458705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT00337454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 50mg BID, once daily, 24 weeks.
Study NCT03541811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3-d gait examination (level walking)
Description: Instrumented 3d-gait-analysis will be carried out in the movement lab of the FH (Fachhochschule; University of Applied Sciences) Campus Wien - University of Applied Sciences. The system used is a 10 camera T40S Vicon system with two floor-mounted AMTI OR6/7-2000 force plates. For assessing gait the Plug-in-Gait Lower Body Model with 14 mm retroreflective skin-mounted markers is implemented in the capturing software Vicon Nexus 2.2. The specific parameters will be extracted from the reporting software Vicon Polygon 4.2.~Markers will be placed by one experienced examiner. Subjects will be instructed to walk barefoot on a 10 meters walkway at self-paced walking speed until five right and five left valid first force plate strikes are captured.
Study NCT00337454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70mg BID, once daily, 24 weeks.
Study NCT03541811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometrics and body composition assessment
Description: Body height will be measured with the stadiometer Seca 213 to the next 0.1cm. Body size and weight will be measured without shoes and outerwear. A correction of 1 kg will be subtracted for clothing. Body weight and body composition will be assessed with the medical body composition analyzer Seca mBCA 515 based on bioelectric impedance analysis.
Study NCT00629057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-PRO
Description: 2 x 10e8 TCID50 q 4 wks x 6
Study NCT00629057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-PRO
Description: 4 x 10e8 TCID50 q 4 wks x 6
Study NCT03294122 — intervention group
Intervention type: RADIATION
Intervention: External beam radiotherapy for prostate cancer
Description: Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.
Study NCT03294122 — intervention group
Intervention type: RADIATION
Intervention: External beam radiotherapy for head and neck cancer
Description: Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
Study NCT02986256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking pictures
Description: Photograph of foot ulcer with transmission to referring nurse 1 time per week
Study NCT02986256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit at home
Description: Home visit by the referring nurse every 15 days
Study NCT03064867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Beginning with 400mg daily on days 1-10 of cycle 1-3~Phase I dose escalation scheme:~Dose Level -2 (DL-2): 100 mg daily, days 1-10, cycle 1-3~DL-1: 200 mg daily, days 1-10, cycle 1-3~DL1: 400 mg daily, days 1-10, cycle 1-3~DL2: 600 mg daily, days 1-10, cycle 1-3~DL3: 800 mg daily, days 1-10, cycle 1-3~Phase II: Given at a dose of 400mg daily for 5 days
Study NCT03064867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Part of R-ICE treatment:~Rituximab: 375 mg/m\^2 intravenously (IV) on Day 1 of R-ICE every 21 days
Study NCT03064867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Part of R-ICE treatment:~Ifosfamide: 5,000 mg/m\^2 mixed together with mesna at a dose of 5,000 mg/m\^2 over 24 hours beginning on Day 2 and completing on Day 3 of each 21-day cycle
Study NCT03064867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Part of R-ICE treatment:~Carboplatin: At a dose corresponding to an AUC = 5 based on Cockcroft-Gault calculation of GFR using adjusted body weight. Carboplatin is given IV on the Day 2 of RICE of each 21 day cycle
Study NCT03541811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers
Description: Blood will be collected into Vacuette serum-separating tubes and will be kept at room temperature for 30 min. Samples will be centrifuged at 1500g for 10 min and serum aliquots will be stored at 80 C until use. Urine samples will be collected into Vacuette tubes containing no additive from non-fasted individuals between 8:00 and 12:00 a.m. Urine samples will be kept at 4 °C for a maximum of 8 h, and then aliquoted and stored at 80 °C.~All biomarkers (except vitamin D and CRP) will be measured in duplicates using standard enzyme-linked immunosorbent assay (ELISA) kits. Serum samples will be assessed for the level of sCOMP, sC1,2C, and sCS846, IL-6, IL-1, sTNFR1 and sTNFR2. Vitamin D and CRP will be measured using automated immunoassay. In urine samples uCTX-II will be determined and these levels will be corrected for creatinine levels (Jaffé method, in-house validated method).
Study NCT03064867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Part of R-ICE treatment:~Etoposide: 100 mg/m2by IV daily on 3 consecutive days (Days 1-3) of each 21-day cycle
Study NCT01874041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Study NCT01874041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Study NCT03318757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Extended Release Liposome Injection
Description: Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
Study NCT03318757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 10ml of Bupivacaine HCl 0.5% will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
Study NCT00901524 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Peg-interféron alpha 2a + ribavirin
Description: Pilot study, multicenter, open label
Study NCT01096641 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: immediate CBT
Description: After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients
Study NCT01096641 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed CBT
Description: After the baseline assessment the fatigued patients will be randomized: this group is to be placed on a waiting list. After 6 months, a second assessment will take place in the group of fatigued patients who received CBT immediately after randomization. This assessment will include the same measurements as at baseline. The fatigued patients on the waiting list will then start with CBT.
Study NCT01916694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue tooth enabled glucose meter with smart phone application
Study NCT00337454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 90mg BID, once daily, 24 weeks.
Study NCT01916694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self home blood glucose monitoring
Description: Fingerprick testing of blood glucose levels before and 2 hours after meals
Study NCT01916694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self home blood glucose monitoring
Description: Fingerprick testing of blood glucose levels before and 2 hours after meals
Study NCT00337454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70mg BID, once daily, 12 weeks.
Study NCT04195672 — intervention group
Intervention type: DEVICE
Intervention: NIPE (MDoloris®) and CBS values
Description: During different procedures of care with the bed-side nurse, NIPE ware recorded. Monitoring started 15 minutes before care and continuously recorded until 10 minutes after the procedure. Pain assessment was evaluated by the CBS under 3 periods for each patient: 1- before any procedure (T1) representing the baseline, 2- during the procedure of care (T2), and 3- after the procedure (T3). Investigator who performed the CBS was blind to NIPE during the procedure recording.~This study did not change the procedure of care before or after and had no impact on care
Study NCT02062255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02062255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 FFA
Study NCT03471286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.
Study NCT03275623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
Study NCT03275623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Prenatal Care
Description: Continued surveillance of urinary cultures
Study NCT03393975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX930
Description: Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg BAX 930 ORT during Period 1 and Period 2 and switch to BAX 930 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of BAX-930.
Study NCT00929006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone suspension
Description: Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
Study NCT00929006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Study NCT01728987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: as in arm description
Study NCT01728987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule looking identical to the cholecalciferol capsule
Study NCT04002869 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunologic, molecular, metabolomic and radiolologic diagnostic
Description: Evaluation and development of new technologies
Study NCT03393975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will receive Investigator-recommended Standard of care (SoC).
Study NCT02602236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AOS-C2000-B
Description: 1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
Study NCT04180813 — intervention group
Intervention type: DRUG
Intervention: Linagliptin
Description: drug
Study NCT01941342 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatoduodenectomy
Study NCT01941342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENBD and Pancreatoduodenectomy
Study NCT04090658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B
Description: Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
Study NCT04090658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
Study NCT04180813 — intervention group
Intervention type: DRUG
Intervention: Acarbose
Description: drug
Study NCT02046343 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health education
Description: Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
Study NCT02046343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
Study NCT02046343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.
Study NCT02046343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newsletter
Description: Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.
Study NCT02046343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Change
Description: Create a site atmosphere that promotes PA and increases the number of PA program offerings.